Literature DB >> 33575974

Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.

M M Moura1, R A Cabrera2, S Esteves3, B M Cavaco4, P Soares5,6,7, V Leite4,8,9.   

Abstract

PURPOSE: Medullary thyroid carcinoma (MTC) displays a wide variety of histopathological features, and several histological variants have been described. In follicular cell-derived thyroid carcinomas, there is a good correlation between genotype and phenotype. In this study, we investigated whether such a correlation is also present in MTC.
METHODS: The histopathological features were evaluated in a series of 66 molecularly characterised tumours and correlated with the clinical characteristics.
RESULTS: Most MTC exhibited the classical variant (83.3%). Other variants included spindle cell (6.1%), pseudopapillary (4.5%), paraganglioma-like (3.0%), angiosarcoma-like (1.5%), and oncocytic follicular (1.5%). Tumours were classified into four groups: group 1, with somatic p.Met918Thr and p.Ala883Phe RET mutations; group 2, with other RET mutations; group 3, with RAS mutations; and group 4, without RET or RAS mutations. Tumours from groups 1 and 4 were typically associated with the classical variant, with abundant fibrosis, lymphovascular invasion, extrathyroidal extension, and more advanced stages of disease, whereas group 2 included histological variants other than the classical variant (namely, pseudopapillary and paraganglioma-like), with tumours that were highly cellular, less invasive, and with a better overall prognosis. In tumours from group 4, amyloid deposition was characteristically absent or low. The spindle cell variant appeared only in tumours from group 3, which had high cellularity and a degree of invasion and prognosis intermediate between groups 1 and 2, but better than group 4. The grade of fibrosis correlated directly with the clinical outcome.
CONCLUSION: Our results support the idea that a genotype-phenotype correlation does, indeed, exist in MTC. However, further studies are warranted to confirm these findings in a larger sample size.
© 2021. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Genotype–phenotype correlation; Histopathological features; Medullary thyroid carcinoma; Prognosis; Tumour fibrosis

Mesh:

Substances:

Year:  2021        PMID: 33575974     DOI: 10.1007/s40618-020-01456-6

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

2.  High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

Authors:  Margarida M Moura; Branca M Cavaco; António E Pinto; Valeriano Leite
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

3.  Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature.

Authors:  E Prokopakis; M Doulaptsi; A Kaprana; S Velegrakis; Y Vlastos; G Velegrakis
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

4.  Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

Authors:  Sanziana Roman; Rong Lin; Julie Ann Sosa
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

5.  Detection of Molecular Alterations in Taiwanese Patients with Medullary Thyroid Cancer Using Whole-Exome Sequencing.

Authors:  Ya-Sian Chang; Chun-Chi Chang; Hsi-Yuan Huang; Chien-Yu Lin; Kun-Tu Yeh; Jan-Gowth Chang
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 6.  RAS proto-oncogene in medullary thyroid carcinoma.

Authors:  Margarida M Moura; Branca M Cavaco; Valeriano Leite
Journal:  Endocr Relat Cancer       Date:  2015-10       Impact factor: 5.678

7.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

Review 8.  Update on medullary thyroid cancer.

Authors:  Mimi I Hu; Anita K Ying; Camilo Jimenez
Journal:  Endocrinol Metab Clin North Am       Date:  2014-06       Impact factor: 4.741

9.  Revising the embryonic origin of thyroid C cells in mice and humans.

Authors:  Ellen Johansson; Louise Andersson; Jessica Örnros; Therese Carlsson; Camilla Ingeson-Carlsson; Shawn Liang; Jakob Dahlberg; Svante Jansson; Luca Parrillo; Pietro Zoppoli; Guillermo O Barila; Daniel L Altschuler; Daniela Padula; Heiko Lickert; Henrik Fagman; Mikael Nilsson
Journal:  Development       Date:  2015-09-22       Impact factor: 6.868

10.  Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

Authors:  M M Moura; B M Cavaco; A E Pinto; R Domingues; J R Santos; M O Cid; M J Bugalho; V Leite
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more
  2 in total

Review 1.  Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Authors:  Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 3.943

Review 2.  Is Encapsulated Medullary Thyroid Carcinoma Associated With a Better Prognosis? A Case Series and a Review of the Literature.

Authors:  Andrea Contarino; Alessia Dolci; Marco Maggioni; Francesca Maria Porta; Gianluca Lopez; Uberta Verga; Francesca Marta Elli; Elisabetta Francesca Iofrida; Gianmaria Cantoni; Giovanna Mantovani; Maura Arosio
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.